Concord Biotech Ltd

Concord Biotech Limited's Board of Directors has approved the unaudited standalone and consolidated financial results for the second quarter and half-year ended September 30, 2026. The Board also fixed November 4, 2026, as the record date for the allotment of bonus equity shares. Additionally, the company announced the reconstitution of its Audit Committee, Nomination and Remuneration Committee, Risk Management Committee, and Corporate Social Responsibility Committee. The statutory auditors, BSR & Co. LLP, have issued their Limited Review Reports on the financial results.

Concord Biotech Ltd announced that its Board of Directors, in a meeting held on October 27, 2026, has fixed Wednesday, November 04, 2026, as the record date for the issuance of bonus equity shares. The company will issue one bonus equity share for every one existing fully paid-up share held, a ratio of 1:1. This corporate action is subject to statutory and regulatory approvals. The deemed date of allotment for these bonus shares is November 05, 2026.

Concord Biotech's consolidated revenue rose 25.1% YoY to ₹309.07 Cr (and 20.0% QoQ from ₹257.49 Cr), while consolidated PAT grew a slower 10.3% YoY to ₹69.57 Cr (+20.6% QoQ from ₹57.70 Cr) — profit growth clearly trailing topline growth on a year-on-year basis, which is the number that matters here over the sharper sequential PAT jump. Both figures land inside the range our pre-result preview flagged (revenue +22-28% YoY, PAT margin 21-23%): actual NPM came in at 21.8%, squarely inline with expectations and with no street preview numbers found for this specific print beyond our own. Against management's FY27 guidance of >25% CAGR growth and a 40%-by-FY28 EBITDA margin path (from 32% at the Q1 call), this quarter's 25.1% YoY growth keeps pace with the growth target, and OPM at 33.87% is a step up from Q1's 31.99%, so the margin trajectory is on track even though it is still running below both the FY28 target and last year's 35.82%. The YoY margin compression (OPM 35.82%→33.87%, NPM 24.22%→21.79%) is the real story behind the print. Employee benefit expense rose 17.7% YoY and power & fuel costs rose 28.4% YoY — consistent with management's own framing of injectable-facility ramp costs and operating leverage building gradually rather than instantly — while other income fell 23.8% YoY to ₹10.17 Cr from ₹13.35 Cr, further pressuring PBT. Sequentially, margins did expand (NPM 21.34%→21.79%, OPM 31.99%→33.87%), so the compression is a YoY phenomenon layered on top of a QoQ improvement, not a deteriorating trend quarter-on-quarter. Standalone tells a materially stronger story: standalone PAT grew 20.4% YoY to ₹75.71 Cr, roughly double the consolidated PAT growth rate — a gap worth flagging since readers will see both numbers. The divergence traces to the consolidation of Celliimune Biotech (acquired April 2026) and another unreviewed subsidiary that posted a ₹4.51 Cr net loss this quarter, plus a ₹0.66 Cr loss from the Concord Biotech Japan JV (versus a ₹1.28 Cr profit in Q1). None of these entities contribute meaningfully to revenue yet, so they show up as pure drag on consolidated profitability. Separately, Unit II cleared its USFDA inspection with only a minor observation (Sep 18, 2026) — a clean regulatory outcome that supports the export-led growth narrative from Q1 — and the board's 1:1 bonus issue (approved Sep 23) has its record date fixed for Nov 4, 2026, so the current quarter's EPS of ₹6.65 is still on the pre-bonus share base. Going into H2 FY27, the quarter sets up two things to track: whether the subsidiary-level losses narrow as Celliimune and the newer units mature, and whether OPM continues its sequential climb back toward the 35%+ territory of a year ago en route to the 40%-by-FY28 target.

Concord Biotech Ltd has announced that its Board of Directors will convene on Tuesday, October 27, 2026. The primary agenda item is the consideration and approval of the unaudited standalone and consolidated financial results for the second quarter and half-year ended September 30, 2026. The Statutory Auditors will also issue their Limited Review Report. Concurrently, the trading window for the company's securities will remain closed until 48 hours after the declaration of these financial results, in adherence to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Concord Biotech Limited's Board of Directors has approved a 1:1 bonus share issuance, meaning one bonus share for every one held, capitalized from the share premium account. Additionally, the company will increase its authorized share capital from ₹11 crore to ₹22 crore by creating 11 crore new equity shares. Both proposals are subject to shareholder approval. The board meeting was held on September 23, 2026.

Concord Biotech Ltd has announced that its Board of Directors will convene on September 23, 2026, to consider and approve a proposal for the declaration of bonus equity shares to existing shareholders. This decision is subject to shareholder approval. Additionally, the company has closed its trading window for designated persons and their relatives from September 19, 2026, until 48 hours after the board meeting's outcome, reopening on September 26, 2026, in compliance with SEBI regulations.

Concord Biotech announced the successful conclusion of a USFDA inspection at its Unit II formulation facility in Valthera, Gujarat. The inspection resulted in a single minor procedural observation, which is not related to Good Manufacturing Practices (GMP). The company will submit a comprehensive response to this observation within the stipulated timeline. Concord Biotech does not anticipate any material impact on its current business operations or existing supplies from this facility due to this development. The USFDA has issued one minor observation which is procedural in nature and not related to GMP.

Concord Biotech Limited announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The Board of Directors, following a review by the Audit Committee, approved these results. The company submitted the results along with a Limited Review Report from its statutory auditors, BSR & Co. LLP, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board meeting commenced at 3:30 PM and concluded at 4:35 PM on July 31, 2026. The limited review report indicates no material misstatements were found in the accompanying financial statements.

Concord Biotech opened FY27 with a clear rebound after a soft FY26. Q1 consolidated revenue from operations rose 26.2% YoY to ₹257.5 Cr and net profit (attributable to owners) rose ~33% to ₹58.5 Cr (₹57.7 Cr PAT for the period after a ₹0.8 Cr non-controlling loss), against ₹204.0 Cr and ₹44.1 Cr a year ago. Margins moved the right way on both lines: operating margin expanded to ~32.0% from 30.1%, and net margin to ~22.7% from 20.2%, with the print carrying no exceptional items this quarter — so the reported growth is the underlying growth, not an optics effect. EPS was ₹5.52 vs ₹4.21. The result validates management's own guidance from the Q3 FY26 concall, where it flagged FY26 as below historical averages but guided FY27 back toward historical growth with potential acceleration to a ~25% CAGR as the injectable facility, CDMO partnerships and new launches scale. A 26% YoY topline in the very first quarter sits squarely on that path. The margin recovery also aligns with management's claim that core business margins remain stable (~40% at the core level) even as new ventures carry start-up costs — the consolidated drag from those ventures is visible in the standalone-vs-consolidated gap: standalone PAT grew 43.8% YoY (to ₹61.2 Cr) versus 31% consolidated, because loss-making subsidiaries (Celliimune, acquired Apr 2, 2026; Stellon Biotech) dilute the group number. Readers seeing the higher standalone figure elsewhere should treat consolidated as the true group picture. Against the sequential quarter, revenue fell 21% and PAT 35% versus Q4 FY26 (₹326 Cr / ₹88.5 Cr), but Q4 is seasonally Concord's strongest quarter and that step-down is a seasonality artifact, not a deterioration — the YoY comparison is the signal here. Concurrent developments support the recovery read: Unit-II cleared Kenya and Uganda regulatory inspections in June, and the board declared the quarter alongside a final dividend (July 24 record date) and the 41st AGM. No formal quarterly guidance or published street consensus was available for this print; the FY26 base had seen consolidated revenue decline ~12%, so this quarter is the first concrete evidence of the guided turnaround taking hold. Management will detail the recovery on its August 3 earnings call.

Concord Biotech Ltd has scheduled a Board of Directors meeting for July 31, 2026. The primary agenda is to consider and approve the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, along with the limited review report from the statutory auditors. Additionally, the company confirmed that the trading window for dealing in its securities will remain closed until 48 hours after the declaration of these financial results, in compliance with SEBI regulations and the company's code of conduct regarding insider trading.